Changes in skin-test reactivity do not correlate with clinical efficacy of H1-blockers in seasonal allergic rhinitis.
New-generation H1-blockers may possess antiallergic properties, and their effect may differ, depending on the target organ. A double-blind, placebo-controlled, parallel-group study was carried out during the pollen season to compare the clinical effect on nasal and conjunctival symptoms of astemizole (10 mg o.d.) and loratadine (10 mg o.d.) with their effect on skin-test reactivity to allergen and histamine. Thirty-eight patients (12-56 years of age) were studied. Nasal and ocular symptoms were recorded daily from days 4 to 7. Skin prick tests with serial concentrations of allergens and one concentration of histamine were carried out before and at the end of the 7-day treatment period. Parallel-line bioassay, analysis of variance, and covariance were used to analyze skin test data. Loratadine and astemizole significantly decreased symptoms from baseline (P < 0.004 and P < 0.006). Skin-test reactivity to allergen and histamine was more profoundly decreased by astemizole than loratadine. The histamine covariant was more important in the allergen effect of astemizole than in that of loratadine. Two H1-blockers having the same clinical effect on nasal and ocular symptoms during the pollen season have totally different effects on skin-test reactivity. Skin-test reactivity to allergen or histamine is not predictive of the clinical efficacy of H1-blockers during seasonal allergic rhinitis.
Service des Maladies Respiratoires, Hôpital Arnaud de Villeneuve, Montpellier, France.
J
J
Bousquet
W
W
Czarlewski
J
J
Cougnard
M
M
Danzig
F B
FB
Michel
D000293:Adolescent; D000328:Adult; D000485:Allergens / Q000276:immunology; D016589:Astemizole / Q000627:therapeutic use*; D002648:Child; D003228:Conjunctiva / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006632:Histamine / Q000276:immunology; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006801:Humans; D017336:Loratadine / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009666:Nose / Q000503:physiopathology; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy* / Q000276:immunology* / Q000503:physiopathology; D012882:Skin Tests; D016896:Treatment Outcome
D000485:Allergens; D006634:Histamine H1 Antagonists; D017336:Loratadine; D016589:Astemizole; D006632:Histamine